Therefore, we conclude that the expression level of TNFRSF9 in TI-Tregs is a novel biomarker that can predict the prognosis of anticancer treatment and response to anti-PD-1 immunotherapy in human lung cancer. Here, TNFRSF9 is linked to lung carcinoma.